Skip to main content

Insight Molecular Diagnostics Inc.

IMDX
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001642380

No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Insight Molecular Diagnostics Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of IMDX: Q1 2026 compared with Q2 2026
MeasureQ1 2026Q2 2026Change
Holders4140−1
Shares18.9M18.5M−473.7K (−2.5%)
Value$62.1M$108.9M+$46.8M (+75.4%)

New holders (12)

Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to IMDX in Q2 2026
InstitutionSharesValue% of portfolio
Jane Street Group, LLC157,682$930.3K0.00%
Jefferies Financial Group Inc.18,100$106.8K0.00%
Marshall Wace, LLP16,597$97.9K0.00%
ExodusPoint Capital Management, LP14,029$82.8K0.00%
Axq Capital, LP13,407$79.1K0.01%
Two Sigma Investments, LP11,101$65.5K0.00%
Tower Research Capital LLC (TRC)2,691$15.9K0.00%
Steward Partners Investment Advisory, LLC1,960$11.6K0.00%
Royal Bank of Canada251$1.00K0.00%
Jones Financial Companies LLLP63$3400.00%
Wells Fargo & Company7$410.00%
Global Retirement Partners, LLC1$60.00%

Sold out (13)

Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2026 and filed for Q2 2026 without it.